Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635946 | 0.95 | ALOX5 (0.55) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7640337 | 0.94 | MAPT (0.57) | ALOX5HDAC1HDAC2SMN1; SMN2PLAAT3 | |
| SCHEMBL8814990 | 0.94 | MAPT (0.57) | ALOX5HDAC1HDAC2SMN1; SMN2PLAAT3 | |
| SCHEMBL8816730 | 0.94 | MAPT (0.57) | ALOX5HDAC1HDAC2SMN1; SMN2PLAAT3 | |
| SCHEMBL7642664 | 0.94 | MAPT (0.57) | ALOX5HDAC1HDAC2SMN1; SMN2PLAAT3 | |
| SCHEMBL304796 | 0.90 | L3MBTL1 (0.55) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| Alcohol SCHEMBL28404120 | 0.87 | L3MBTL1 (0.52) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7637978 | 0.85 | HDAC1 (0.61) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL11041861 | 0.84 | PLAAT3 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL11133561 | 0.84 | ALOX5 (0.53) | ALOX5HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5142095-A | Treating inflammation, allergies, asthma, cardiovascular disorders, psoriasis | WARNER-LAMBERT COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| US-4680392-A | Substituted caprolactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4629787-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4594341-A | Hypotensive agent | MERCK & CO., INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4587050-A | Substituted enantholactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0046291-B1 | SUBSTITUTED CAPROLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0068173-B1 | PERHYDRO-1,4-THIAZEPIN-5-ONE AND PERHYDRO-1,4-THIAZOCIN-5-ONE DERIVATIVES, PROCESS FOR PREPARING AND PHARMCEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1984-09-26 | — | — | EP | disclosed |
| EP-0068173-A1 | Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same | MERCK & CO. INC. (US) | 1983-01-05 | — | — | EP | disclosed |
| EP-0065301-A1 | Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-11-24 | — | — | EP | disclosed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | ALOX5 1605/4885HDAC3 527/4885HDAC1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.